Document:

Exhibit

Exhibit 10.9

Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Triple asterisks denote omissions

NINTH AMENDMENT TO
SECOND AMENDED AND RESTATED DISTRIBUTION AGREEMENT

This Ninth Amendment to Second Amended and Restated Distribution Agreement (this “Amendment”) is between The Medicines Company, a Delaware corporation with offices at 8 Sylvan Way, Parsippany, NJ 07054 (“MDCO”), and Integrated Commercialization Solutions, LLC, f/k/a Integrated Commercialization Solutions, Inc., a California limited liability company with offices at 3101 Gaylord Parkway, Frisco, TX 75034 (“Distributor”).  This Amendment is effective as of October 3, 2017 (the “Amendment Effective Date”).  MDCO and Distributor shall, at times throughout this Amendment, be referred to individually as a “Party” and collectively as the “Parties”. 

RECITALS

		
	A.
	MDCO and Distributor are parties to a Second Amended and Restated Distribution Agreement effective as of October 1, 2010, as amended by the First Amendment dated July 1, 2011, the Second Amendment dated September 1, 2011, the Third Amendment dated April 23, 2012, the Fourth Amendment dated April 29, 2013, the Fifth Amendment dated September 12, 2013, the Sixth Amendment dated March 1, 2014, and the Seventh Amendment dated March 5, 2015, and the Eighth Amendment dated April, 2016 (as amended, the “Agreement”);

		
	B.
	Under the Agreement, among other things, MDCO engaged Distributor to perform distribution services for certain of MDCO’s pharmaceutical products; and

		
	C.
	The Parties now wish to amend the Agreement in certain respects.

AMENDMENT

NOW THEREFORE, the parties agree as follows:

		
	1.
	Defined Terms.  Capitalized terms in this Amendment that are not defined in this Amendment have the meanings given to them in the Agreement.  If there is any conflict between the Agreement and any provision of this Amendment, this Amendment will control.

		
	2.
	Exhibit B.  The Parties agree that Exhibit B to the Agreement is hereby deleted in its entirety and replaced with the attached Revised Exhibit B.

		
	5.
	No Other Changes.  Except as otherwise provided in this Amendment, the terms and conditions of the Agreement will continue in full force, nothing in the Amendment modifies any term or provision in the Agreement or the Continuing Guaranty.

[Signature Page Follows.]

1

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

	
				
	INTEGRATED COMMERCIALIZATION
SOLUTIONS, INC.
	THE MEDICINES COMPANY

	By:
	/s/ Peter Belden         
	By:
	/s/ Daniel Tokich      

	Name:
	Peter Belden         
	Name:
	_Daniel Tokich         

	Title:
	President         
	Title:
	VP Supply Chain and 3rd Party Operations         

	 
	 
	 
	 

2

EXHIBIT B
Product List

Product Name:                ANGIOMAX® (bivalirudin) for Injection
		
	NDC#:
	65293-001-01

		
	Drug Type:
	RX

		
	Sellable Package Size:
	Carton (10 single use vials)

		
	Dosage Form:
	250mg vial

		
	Current WAC Price*:
	$[***] per Carton, (*which may change from time to time at MDCO’s sole discretion)

		
	Case Pack Size
	Thirty (30) Cartons

		
	Shipping and Storage Requirements:   
	20 to 25°C

		
	Product Name:
	ANGIOMAX® (bivalirudin) Nova Plus for Injection

		
	NDC#:
	65293-004-22

		
	Drug Type:
	RX

		
	Sellable Package Size:
	Carton (10 single use vials)

		
	Dosage Form:
	250mg vial

		
	Current WAC Price*:
	$[***] per Carton, (*which may change from time to time at MDCO’s sole discretion)

		
	Case Pack Size
	Thirty (30) Cartons

		
	Shipping and Storage Requirements:   
	20 to 25°C

Product Name:            Vabomere
NDC:                    65293-009-06
Drug Type:                RX
		
	Sellable Package Size:
	Carton (6 single use vials)

Dosage form:                2g vial
		
	Current WAC Price*
	$[***] Carton, (*which may change from time to time at MDCO’s sole discretion)

Case Pack Size:            Twelve (12) Cartons
Shipping and Storage Conditions:     20 to 25°C

Product Name:            Minocin IV 100 mg Inj    
NDC:                    65293001410
Drug Type:                RX
Sellable Package Size:        Carton (10 single use vials)
Dosage form:                100mg vial
		
	Current WAC Price*
	$[***] Carton, (*which may change from time to time at MDCO’s sole discretion)

3

Case Pack Size:            Twelve (12) Cartons
Shipping and Storage Conditions:     20 to 25°C

Product Name:            Orbactiv
NDC:                    65293001503
Drug Type:                RX
Sellable Package Size:        Carton (3 single use vials)
Dosage form:                400 mg vial
		
	Current WAC Price*
	$[***] Carton, (*which may change from time to time at MDCO’s sole discretion)

Case Pack Size:            Thirty (30) Cartons
Shipping and Storage Conditions:     20 to 25°C

4Exhibit

	
			
	
	8 Sylvan Way
Parsippany, NJ  07054
	EX - 10.29

November 14, 2017

Clive Meanwell
50 Mountaintop Rd
Bernardsville, NJ 07924

Dear Dr. Meanwell: 

Reference is made to that certain Amended and Restated Employment Agreement by and between you and The Medicines Company (the “Company”), dated as of May 26, 2016 (the “Employment Agreement”).  Capitalized terms contained herein but not defined shall have the meanings ascribed to them in the Employment Agreement.

The purpose of this letter (this “Amendment”) is to confirm the parties’ desire and intent to amend the Employment Agreement effective as of the date first written above.  Accordingly, we are pleased to agree as follows:

1.   Section 2 of the Employment Agreement is replaced in its entirety with the following:

“Section 2.  Title; Capacity.   During the Employment Period, the Employee shall serve as the Company’s Chief Executive Officer and have such authority, power, duties and responsibilities as are customary for the chief executive officer of a corporation of the size and nature of the Company, except to the extent that such authority, power, duties and responsibilities have been assigned, as of November 14, 2017, by the Board of Directors of the Company (the “Board”) to the Executive Chairman of the Company, and such other authority, power, duties and responsibilities as may be reasonably assigned to the Employee from time to time by the Board  or the Executive Chairman as of November 14, 2017 (the “Executive Chairman”), and the Employee shall report solely to, and be subject to the supervision of, the Executive Chairman  or, if otherwise determined by the Board, to the Board.   The Employee hereby accepts such employment and agrees to undertake the duties and responsibilities inherent in such position, such other duties and responsibilities as the Board or the Executive Chairman shall from time to time reasonably assign to him, and service on any board of the Company or its affiliates, in each case without additional compensation.  The Employee agrees to devote his entire business time, attention and energies to the business and interests of the Company during the Employment Period.  The Employee agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein which may be adopted from time to time by the Company.  The Employee acknowledges receipt of copies of all such rules and policies committed to writing as of the date of this Agreement.”

     

By signing below, you acknowledge and agree that this Amendment shall not constitute “Good Reason”, as defined in the Severance Agreement, and shall not result in the payment or vesting of any compensation or benefits under the Severance Agreement or any other agreement between you and the Company.  If the foregoing accurately reflects our agreement, kindly sign and return to us the enclosed duplicate copy of this Amendment.
 
 
Very truly yours, 

THE MEDICINES COMPANY 

By:      / s/ Stephen Rodin                        
Name:  Stephen Rodin
Title:   General Counsel

    

Accepted and Agreed to:

  /s/ Clive Meanwell        
Clive Meanwell 

Page 2 of 2Exhibit

                                                

Exhibit 10.10
September 16, 2016                                    

Ms. Tracy Pearson
255 Ridgewood Drive
Piperton, TN  38017

Dear Tracy,

We are pleased to offer you the position of SVP Packaging Solutions with Veritiv Operating Company. This position is based out of Atlanta, Georgia and reports to Mary Laschinger, Chairman and CEO.  Your anticipated start date is on or before October 17, 2016.

You will receive a monthly salary of $37,500 (which equates to $450,000 per year). In accordance with Veritiv’s current payroll practices, your salary will be paid on the last working day of the month. This is a salaried exempt position, which means that you will not be eligible for overtime pay.

This position is eligible for relocation benefits in accordance with Veritiv’s relocation policy. The relocation process is administered by NuCompass. Additional information on this process will be provided to you upon your acceptance of this offer. In addition, if you incur a loss on the sale of your home in excess of the amount reimbursed by the relocation policy, you will receive a cash amount for the unreimbursed loss amount which will be grossed-up for taxes; this amount will not to exceed $400,000 (including the tax gross-up). The relocation benefit is based upon the expectation that you will be employed with the Company for one year or more. Should you voluntarily terminate your employment within 12 months of your start date, you will be required to reimburse the Company for relocation benefits paid to you, or on your behalf, to the extent permitted by applicable law.

If you accept this offer, you will receive a one-time signing bonus in the gross amount of $815,000, which will be paid not later than March 31, 2017.  Please note that the amount paid will be net of applicable tax withholdings. This bonus is based upon the expectation that you will be employed with the Company for two years or more. By accepting this offer, you expressly agree that should you voluntarily terminate your employment or be terminated for cause, you will reimburse the Company for 100% of the bonus if the termination occurs within the first 12 months, 50% of the bonus if the termination occurs after one year and within the first 18 months, and 25% of the bonus if the termination occurs after the first 18 months and within the first 24 months.

In addition to your salary, this position is eligible to participate in Veritiv’s Annual Incentive Plan (AIP). The AIP is an incentive plan that provides you with an opportunity to share in the financial success of the Company through a bonus based on both the Company’s performance and your own individual performance. Subject to the terms of the AIP, your current annual target bonus amount is 70% of your annual base salary, or $315,000. For your initial year of employment, your bonus will be pro-rated for the portion of the performance period that you are employed by the Company and will not be less than $75,000.  For your first full year of employment (2017), your AIP bonus will be calculated using the higher of target (100%) or actual Company performance. For your second full year of employment (2018), your AIP bonus will be calculated using the higher of target (50%) or actual Company performance. The individual performance component remains in effect for all years. 

You will also be eligible to participate in the Veritiv Long-Term Incentive (LTI) Plan. The LTI is an equity incentive plan. Subject to the terms of the LTI, your current target grant value is $540,000. Grants have a 

1000 Abernathy Road NE, Suite 1700, Atlanta, GA 30328  |  770 391 8200  |  veritivcorp.com
Offer Letter – Salaried Exempt

three-year performance period and are paid out at the end of the performance period based on attainment of specified business goals. LTI awards are made in the form of restricted stock (20% of grant value) and performance stock units (80% of grant value). Additional information will be sent to you following the grant date.

You will be eligible for benefits on your first day of employment. Veritiv’s competitive benefits program provides options for medical, dental, vision, and life insurance for you and your dependents, as well as time off, disability and life insurance, retirement savings benefits, and more. You will have 31 days from your eligibility date to enroll in benefits. You will receive information on how to enroll in benefits after your first day of employment.

You will also be eligible for up to five weeks of vacation on an annual accrual basis.

This offer of employment is contingent upon successful completion of a drug screen, background investigation, and reference check. Upon your acceptance of this offer, I will provide you with the necessary forms and instructions to start these processes. 

Pursuant to the Immigration Reform and Control Act (IRCA), you must also verify your identity and authorization to work. Therefore, if you accept this offer, you will be required to complete an I-9 Employment Eligibility Verification Form no later than the first day of employment. Additionally, within three business days of the date your employment begins, you will need to supply acceptable documentation of your identity and work authorization. A complete list of acceptable documents is available at http://www.uscis.gov/sites/default/files/files/form/i-9.pdf. 

Finally, this offer is also contingent upon your signing and returning the enclosed Noncompetition Agreement.

This employment offer is based upon your skills and abilities, not because of confidential, trade secret, or other proprietary information of your former employer(s) which you may have knowledge. By accepting this offer, you expressly agree that:

		
	1)
	You have not retained and will not retain any documents (in whatever form, whether hard copy or electronic) containing confidential, trade secret, or proprietary information belonging to any of your former employers;

		
	2)
	You have maintained and will continue to maintain your duty of loyalty to your former employer until your termination date with that employer;

		
	3)
	During your employment with Veritiv, you will not utilize or disclose any confidential, trade secret, or proprietary information belonging to any of your former employers; and

		
	4)
	If you are subject to a non-compete agreement and/or any other restrictive covenant with a former employer or any other entity, you have advised us of the existence of that restrictive covenant and have truthfully and accurately represented to us your understanding that the restrictive covenant will not prevent you from performing the duties of the position that we have offered you.

Please note that your employment with Veritiv is on an at-will basis and is not guaranteed for any length of time. This means that both you and the Company may terminate the employment relationship at any time, for any reason, with or without cause or notice, and in accordance with applicable law. Additionally, the terms and conditions of your employment, including but not limited to your position, job responsibilities, compensation, and benefits, may be altered by the Company at its sole discretion. 

To accept this offer, please sign this letter and return it to me by September 23, 2016.
 
I am delighted that you are considering joining the Veritiv team and believe that you will find this opportunity to be personally and professionally rewarding. Please feel free to contact me with any questions.

2
Offer Letter – Salaried Exempt

Yours Truly, 

/s/ Elizabeth Patrick
Elizabeth Patrick
SVP, Chief HR Officer

ACCEPTED & AGREED:

/s/ Tracy L. Pearson                September 22, 2016                
Tracy Pearson                        Date

3
Offer Letter – Salaried Exempt

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]